India's government will cap trade margins on 137 cancer drugs following a Supreme Court ruling.

What it means

India's National Pharmaceutical Pricing Authority (NPPA) will cap trade margins (distributor and retailer profits) at 30% of the maximum retail price for 137 cancer drugs. This follows a Supreme Court ruling that highlighted excessive hospital mark-ups, which had made life-saving cancer medications unaffordable. The measure is expected to significantly reduce the cost of these drugs for patients.

Accuracy & sourcesSourced

The claim is solid, based on an official government announcement from the NPPA (via PIB) and a Lancet publication. The reporting closely follows these primary sources, and multiple news outlets confirm the policy details.

How new

This is genuinely new policy, announced in October 2026 and widely reported in the same period.

Go deeper